While the efficacy of PARP inhibitors was first demonstrated against solid tumors with BRCA1/2 mutations and HRR defects, these alterations are not universally present in melanoma patients given the molecular heterogeneity of melanoma (56). The gene discussed is BRCA1; the disease is melanoma.